The evolving treatment paradigm for BRAF V600 mutant colorectal cancer.
作者信息
Kratz Jeremy D, Deming Dustin A
机构信息
Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Department of Oncology, McArdle Laboratory for Cancer Research, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
出版信息
Ann Transl Med. 2019 Dec;7(Suppl 8):S257. doi: 10.21037/atm.2019.12.61.
Abstract
摘要
相似文献
1
The evolving treatment paradigm for BRAF V600 mutant colorectal cancer.BRAF V600 突变型结直肠癌不断演变的治疗模式。
Ann Transl Med. 2019 Dec;7(Suppl 8):S257. doi: 10.21037/atm.2019.12.61.
2
BRAF Non-V600 Mutations in Metastatic Colorectal Cancer.转移性结直肠癌中的BRAF非V600突变
Cancers (Basel). 2023 Sep 17;15(18):4604. doi: 10.3390/cancers15184604.
3
Response to Anti-EGFR Therapy in Patients with BRAF non-V600-Mutant Metastatic Colorectal Cancer.BRAF 非 V600 突变型转移性结直肠癌患者的抗 EGFR 治疗反应。
Clin Cancer Res. 2019 Dec 1;25(23):7089-7097. doi: 10.1158/1078-0432.CCR-19-2004. Epub 2019 Sep 12.
4
BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer.BRAF突变定义了转移性结直肠癌一种临床上独特的分子亚型。
J Clin Oncol. 2017 Aug 10;35(23):2624-2630. doi: 10.1200/JCO.2016.71.4394. Epub 2017 May 9.
5
Targeted Therapy for Colorectal Cancers With Non-V600 BRAF Mutations: Perspectives for Precision Oncology.非V600 BRAF突变型结直肠癌的靶向治疗：精准肿瘤学的前景
JCO Precis Oncol. 2018 Nov;2:1-12. doi: 10.1200/PO.18.00195.
6
Clinical characteristics and course of 63 patients with BRAF mutant lung cancers.63例BRAF突变型肺癌患者的临床特征与病程
J Thorac Oncol. 2014 Nov;9(11):1669-74. doi: 10.1097/JTO.0000000000000344.
7
Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.达拉非尼和曲美替尼联合抑制BRAF和MEK在BRAF V600突变型结直肠癌中的应用
J Clin Oncol. 2015 Dec 1;33(34):4023-31. doi: 10.1200/JCO.2015.63.2471. Epub 2015 Sep 21.
8
A clinicopathologic study of diencephalic pediatric low-grade gliomas with BRAF V600 mutation.BRAF V600 突变的丘脑儿童低级别胶质瘤的临床病理研究。
Acta Neuropathol. 2015 Oct;130(4):575-85. doi: 10.1007/s00401-015-1467-3. Epub 2015 Aug 12.
9
Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib.在肺癌中反复发现的非V600 BRAF突变预示着对曲美替尼和达拉非尼联合用药的敏感性。
Oncotarget. 2016 Aug 26;8(36):60094-60108. doi: 10.18632/oncotarget.11635. eCollection 2017 Sep 1.
10
Encorafenib plus binimetinib in patients with -mutant non-small cell lung cancer: phase II PHAROS study design.恩考芬尼联合比美替尼治疗 - 突变型非小细胞肺癌患者：PHAROS 期临床试验设计。
Future Oncol. 2022 Mar;18(7):781-791. doi: 10.2217/fon-2021-1250. Epub 2021 Dec 17.
引用本文的文献
1
Spectrum of BRAF Aberrations and Its Potential Clinical Implications: Insights From Integrative Pan-Cancer Analysis.BRAF 畸变谱及其潜在临床意义：综合泛癌分析的见解
Front Bioeng Biotechnol. 2022 Jul 14;10:806851. doi: 10.3389/fbioe.2022.806851. eCollection 2022.
本文引用的文献
1
Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406).随机试验伊立替康和西妥昔单抗与或无维莫非尼在 BRAF 突变转移性结直肠癌（SWOG S1406）。
J Clin Oncol. 2021 Feb 1;39(4):285-294. doi: 10.1200/JCO.20.01994. Epub 2020 Dec 23.
2
Atypical, Non-V600 BRAF Mutations as a Potential Mechanism of Resistance to EGFR Inhibition in Metastatic Colorectal Cancer.非典型、非V600 BRAF突变作为转移性结直肠癌中EGFR抑制耐药的潜在机制
JCO Precis Oncol. 2019 Aug 5;3. doi: 10.1200/PO.19.00102. eCollection 2019.
3
Encorafenib, Binimetinib, and Cetuximab in V600E-Mutated Colorectal Cancer.encorafenib、binimetinib 和西妥昔单抗治疗 V600E 突变型结直肠癌。
N Engl J Med. 2019 Oct 24;381(17):1632-1643. doi: 10.1056/NEJMoa1908075. Epub 2019 Sep 30.
4
NCCN Guidelines Insights: Colon Cancer, Version 2.2018.NCCN 指南解读：结肠癌，第 2.2018 版。
J Natl Compr Canc Netw. 2018 Apr;16(4):359-369. doi: 10.6004/jnccn.2018.0021.
5
Combined BRAF, EGFR, and MEK Inhibition in Patients with -Mutant Colorectal Cancer.BRAF、EGFR 和 MEK 联合抑制治疗 - 突变型结直肠癌患者。
Cancer Discov. 2018 Apr;8(4):428-443. doi: 10.1158/2159-8290.CD-17-1226. Epub 2018 Feb 5.
6
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.纳武利尤单抗联合伊匹单抗治疗错配修复缺陷/微卫星高度不稳定转移性结直肠癌的持久临床获益。
J Clin Oncol. 2018 Mar 10;36(8):773-779. doi: 10.1200/JCO.2017.76.9901. Epub 2018 Jan 20.
7
BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer.BRAF突变定义了转移性结直肠癌一种临床上独特的分子亚型。
J Clin Oncol. 2017 Aug 10;35(23):2624-2630. doi: 10.1200/JCO.2016.71.4394. Epub 2017 May 9.
8
A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic -Mutant Colorectal Cancer.恩考芬尼与西妥昔单抗联合或不联合阿培利司用于转移性 BRAF 突变型结直肠癌的 Ib 期剂量递增研究。
Cancer Discov. 2017 Jun;7(6):610-619. doi: 10.1158/2159-8290.CD-16-0795. Epub 2017 Mar 31.
9
Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.RAS/PIK3CA/BRAF肿瘤突变作为转移性结直肠癌患者一线贝伐单抗化疗反应预测指标的回顾性研究。
BMC Cancer. 2017 Jan 9;17(1):38. doi: 10.1186/s12885-016-2994-6.
10
A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer.一项关于MEK1/2抑制剂司美替尼（AZD6244/ARRY-142866）联合西妥昔单抗用于难治性实体瘤和KRAS突变型结直肠癌的I期研究。
Invest New Drugs. 2016 Apr;34(2):168-75. doi: 10.1007/s10637-015-0314-7. Epub 2015 Dec 14.
Zotero 插件